Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Other Non-current Assets

Long-term assets not reported separately.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Other Non-current Assets · Q3 FY2026 · quarter ended Sep 2026

Other non-current assets rises 9.6% from a year ago

Other non-current assets stood at $117.1M at the end of Q3 FY2026, up 9.6% from a year earlier and up 32.2% from the prior quarter. Over 3 fiscal years it compounded at -38.3% a year.

Context

  • Other non-current assets amounted to 1.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Other non-current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether other non-current assets keeps rising in the next quarterly balance sheet after a +9.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$117.1M+32.2% QoQ
Last fiscal yearDec 2025
$102.28M-14.5% YoY
Year agoSep 2025
$106.8M+9.6% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.6%——
1 year-14.5%——
3-year CAGR-38.3%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
102.28M USD
Year-over-year change
-14.5%
4-year CAGR
-26.9%

Other Non-current Assets vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's Sep 2026 other non-current assets of $117.1M is the 3rd highest of the 9 companies compared; the peer median is $25.18M.
  • Its year-over-year change of +9.6% is the 6th highest of 9, against a peer median of +167.4%.
  • Other non-current assets amounts to 1.0% of total assets for JAZZ, versus a peer median of 1.5%.
JAZZ Competitors Peer median
Other Non-current Assets for JAZZ and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NBIXNeurocrine Biosciences, Inc.Sep 2026$291.4M +1335.5%+33.5%5.2%
LGNDLigand Pharmaceuticals IncorporatedJun 2026$217.54M +703.7%+1.0%10.0%
JAZZJazz Pharmaceuticals plcSep 2026$117.1M +9.6%-38.3%1.0%
HRMYHarmony Biosciences Holdings, Inc.Jun 2026$29.82M -85.5%+53.2%2.2%
LEGNLegend Biotech CorporationSep 2026$25.8M +134.8%+49.8%1.5%
TGTXTG Therapeutics, Inc.Sep 2026$24.56M +627.8%+146.5%1.5%
GMABGenmab A/SJun 2026$24M +200.1%-99.8%0.2%
MGNXMacroGenics, Inc.Mar 2026$1.38M -7.7%+0.2%0.6%
INCYIncyte CorporationJun 2026-$104.39M -125.9%—1.3%
Peer median (excluding JAZZ) $25.18M+167.4%+33.5%1.5%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents591.45M881.48M1.51B2.41B1.39B
Short-term Investments00120M580M1.05B
Net Receivables563.36M651.49M705.79M716.77M830.75M
Inventory1.07B714.06M597.04M480.45M416.96M
Other Current Assets252.39M267.19M320.81M261.54M323.95M
Total Current Assets2.61B2.61B3.44B4.63B4.17B
Property, Plant & Equipment (Net)343.42M301.38M234.99M227M258.74M
Goodwill1.83B1.69B1.75B1.72B1.83B
Intangible Assets7.15B5.79B5.42B4.76B4.43B
Long-term Investments5M5.5M04.33M4.3M
Tax Assets00477.83M560.25M869.13M
Other Non-current Assets358.95M435.14M73.94M119.64M102.28M
Total Non-current Assets9.69B8.23B7.96B7.38B7.49B
Total Assets12.3B10.84B11.39B12.01B11.66B
Account Payables100.3M90.76M102.75M77.87M122.06M
Short-term Debt31M31M604.95M31M1.03B
Tax Payables9.61M7.72M35.07M18.76M56.39M
Deferred Revenue2.09M463K000
Other Current Liabilities193.1M169.41M142.33M189.76M245.99M
Total Current Liabilities809.3M933.19M1.54B1.04B2.24B
Long-term Debt6.02B5.69B5.11B6.08B4.33B
Deferred Tax Liabilities1.3B944.34M847.71M676.74M594.47M
Deferred Revenue (Non-current)463K0000
Other Non-current Liabilities117M106.81M104.75M86.61M124.52M
Total Non-current Liabilities7.52B6.82B6.12B6.88B5.1B
Total Liabilities8.33B7.75B7.66B7.92B7.34B
Common Stock61K61K61K61K6K
Retained Earnings830.23M733.59M878.66M1.13B646.18M
Accumulated OCI(400.36M)(1.13B)(842.15M)(947.67M)(568.6M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity3.97B3.09B3.74B4.09B4.32B
Total Debt6.15B5.81B5.79B6.16B5.42B
Net Debt5.56B4.93B4.29B3.75B4.03B

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.